SCHEMBL19665275

SCHEMBL19665275

Cc1ccc(O[C@@H]2[C@H](n3cc(-c4cc(F)c(F)c(F)c4)nn3)[C@@H](O)[C@@H](S)O[C@@H]2CO)cc1

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 20/20 0.60
▸ LGALS1 P09382 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17993057 0.82 LGALS3 (0.75) LGALS3LGALS1
SCHEMBL17964039 0.82 LGALS3 (0.75) LGALS3LGALS1
SCHEMBL17993172 0.80 LGALS3 (0.66) LGALS3LGALS1
SCHEMBL28632466 0.77 LGALS3 (0.61) LGALS3LGALS1
SCHEMBL19665270 0.77 LGALS3 (0.54) LGALS3LGALS1
SCHEMBL22399196 0.75 LGALS3 (0.67) LGALS3LGALS1
SCHEMBL19680684 0.75 LGALS3 (1.00) LGALS3
SCHEMBL17964140 0.75 LGALS3 (1.00) LGALS3
SCHEMBL17993229 0.75 LGALS3 (1.00) LGALS3
SCHEMBL22852679 0.75 LGALS3 (1.00) LGALS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377464-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2022-07-05 — — US claimed
EP-3250581-B1 ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS GALECTO BIOTECH AB (DK) 2021-01-20 — — EP claimed
US-20200407391-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS GALECTO BIOTECH AB (DK) 2020-12-31 — — US claimed
US-10774102-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2020-09-15 — — US claimed
US-20170349619-A1 ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS GALECTO BIOTECH AB (DK) 2017-12-07 — — US claimed
US-11919921-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2024-03-05 — — US disclosed
US-11377464-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2022-07-05 — — US disclosed
CN-113621005-A alpha-D-galactoside inhibitors of galectins 格莱克特生物技术公司 2021-11-09 — — CN disclosed
CN-107406478-B alpha-D-galactoside inhibitors of galectins 格莱克特生物技术公司 2021-07-27 — — CN disclosed
EP-3828191-A2 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS Galecto Biotech AB (DK) 2021-06-02 — — EP disclosed
EP-3250581-B1 ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS GALECTO BIOTECH AB (DK) 2021-01-20 — — EP disclosed
US-20200407391-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS GALECTO BIOTECH AB (DK) 2020-12-31 — — US disclosed
US-10774102-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2020-09-15 — — US disclosed
US-20170349619-A1 ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS GALECTO BIOTECH AB (DK) 2017-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200407391-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS LGALS1, LGALS3, LGALS2 LGALS3 2/4885LGALS1 1/4885
US-11377464-B2 Galactoside inhibitor of galectins LGALS3, LGALS1, LGALS2 LGALS3 1/4885LGALS1 2/4885
US-11919921-B2 Galactoside inhibitor of galectins LGALS3, LGALS1, LGALS2 LGALS3 1/4885LGALS1 2/4885
US-20170349619-A1 ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS LGALS3, LGALS1, LGALS2 LGALS3 1/4885LGALS1 2/4885
US-10774102-B2 Galactoside inhibitor of galectins LGALS3, LGALS1, LGALS2 LGALS3 1/4885LGALS1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback